AJICAP Technology Confirms Precise Drug Attachment at Lys248 on Antibodies for Uniform Cancer Drug Conjugates | Research

The takeaway

AJICAP chemical conjugation technology produces site-specific antibody-drug conjugates at Lys248 in the Fc region, confirmed by peptide mapping with >93% sequence coverage.

>93% sequence coverage
Single enzymatic digestion achieved >93% coverage confirming Lys248 site-specificity

What the researchers found

AJICAP conjugation occurs specifically at Lys248 in the Fc region, confirmed by MS/MS and peptide mapping with >93% sequence coverage.

Why it matters

ADC manufacturing requires proving where exactly drugs attach to antibodies. AJICAP's confirmed site-specificity enables more consistent, regulatory-compliant cancer drug manufacturing.

The numbers in context

Lys248 conjugation site; >93% sequence coverage; neutral pH pretreatment; HIC-HPLC purification

How the study worked

Peptide mapping with neutral pH pretreatment; MS/MS fragmentation analysis; extracted ion chromatography; preparative HIC-HPLC purification; >93% sequence coverage from single enzymatic digestion.

Who was studied

AJICAP first-generation antibody-drug conjugate analytical characterization

What this study cannot tell us

Analytical characterization only — no biological activity or in vivo efficacy data; single antibody tested; manufacturing scale-up not addressed.

How to read the evidence

Low — analytical chemistry proof-of-concept; no biological or clinical data.

When this study was published

Published in 2020; AJICAP technology has continued to advance in the ADC field.

The bigger picture

Site-specific ADCs are the future of targeted cancer therapy. Proving exact conjugation sites is critical for regulatory approval and is advancing the ADC field toward more precise medicines.

Questions still open

Does Lys248 conjugation affect antibody effector functions?
How does AJICAP ADC efficacy compare to random conjugation ADCs in tumors?
Can AJICAP achieve higher drug-to-antibody ratios while maintaining site-specificity?

Common questions

Why does it matter where drugs attach to antibodies?

Random attachment creates a mix of products with variable potency and toxicity. Site-specific attachment at one defined position creates a uniform product that's easier to manufacture, test, and approve.

What is AJICAP?

A chemical platform that uses Fc-binding reagents to attach drugs to antibodies at a specific amino acid (Lys248), producing uniform antibody-drug conjugates for cancer treatment.

Read the original research

Proof of site-specificity of antibody-drug conjugates produced by chemical conjugation technology: AJICAP first generation.

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 1140, 121981

View on PubMed ↗Publisher’s paper ↗

Citation

Matsuda, Yutaka; Malinao, Maria-Christina; Robles, Veronica; Song, James; Yamada, Kei; Mendelsohn, Brian A. (2020). Proof of site-specificity of antibody-drug conjugates produced by chemical conjugation technology: AJICAP first generation.. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 1140, 121981. https://doi.org/10.1016/j.jchromb.2020.121981